Post-earnings recap
Reported
Tue, Jan 29, 2013
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
Boston Scientific's strong EPS performance, exceeding expectations significantly, led to a 3.5% increase in stock price. Investors reacted positively to the company's ability to outperform on earnings, even without revenue figures or specific guidance. The management's optimistic tone suggests confidence in future growth, which may further bolster investor sentiment.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.18 | N/A | +65.14% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a positive outlook on the company's performance. They emphasized their commitment to innovation and market expansion.
Management highlighted strong performance in key product areas.
They expressed confidence in future growth despite not providing specific guidance.
Est. EPS
—
Est. Rev
—
Impl. Move
—